

Westminster Health Forum policy conference:

Next steps for medicine regulation in the UK

Timing: Morning, Thursday, 2nd October 2025

Taking place online



WESTMINSTER
HEALTH FORUM

Draft agenda subject to change

- 8.30 Registration
- 9.00 **Chair's opening remarks**
Senior Parliamentarian
- 9.05 **Supporting the safe regulation of new personalised therapies and streamlining patient access pathways**
Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine and Honorary Consultant Physician, University of Liverpool; Director, Centre for Drug Safety Science and Wolfson Centre for Personalised Medicine; and Chair, Highly Personalised Medicines Expert Working Group
Questions and comments from the floor
- 9.30 **The way forward for personalised therapies - regulation, patient access and system readiness**
preparing the NHS for deployment of new personalised technologies | diagnostics and pathways for patient access | increasing access to clinical trials | the future of individualised mRNA cancer immunotherapies | next steps for cell and gene therapies | pharmacovigilance and priorities for personalised medicine | developing guidance on regulatory models for whole genome sequencing and other early intervention technologies | regulatory alignment in prescribing settings | opportunities for international regulatory alignment | decentralised manufacturing
Senior representative, industry
Senior representative, NHS
Senior representative, patient group
Senior representative, research
Senior commentator
Questions and comments from the floor
- 10.20 **Priorities for collaboration in improving patient access to innovation**
Senior representative, guidelines
Questions and comments from the floor
- 10.45 **Chair's closing remarks**
Senior Parliamentarian
- 10.50 Break
- 11.00 **Chair's opening remarks**
Senior Parliamentarian
- 11.05 **Making the UK an attractive place for medicine research and development**
Dr Dan O'Connor, Director, Regulatory and Early Access Policy, Association of the British Pharmaceutical Industry
- 11.15 **Clinical trial regulation reform - strategies for improving inclusivity and public trust**
Senior representative, research
- 11.25 Questions and comments from the floor
- 11.40 **Streamlining access to innovation - next steps for emerging technologies, priorities for regulation following the Life Sciences Sector Plan, and plans for innovation and prevention in the 10-Year Health Plan**
updated Innovative Licensing and Access Pathway and developer access to early engagement | post-market surveillance, notification requirements and corrective action | role of the Regulatory Innovation Office | upcoming DHSC investment and priorities from the 2025 Spending Review | implementation of new medical device regulations | ensuring patient safety while progressing innovation | adapting regulatory frameworks as technologies become more complex | developing evidence for new AI technologies | use of environmental data in regulatory and procurement decisions | next steps for Centres of Excellence in Regulatory Science and Innovation | priorities for international alignment | role of regulation in supporting digital transformation and promoting preventative strategies
Senior representative, innovation
Senior representative, industry
Senior representative, AI
Senior representative, legal
Senior academic
Questions and comments from the floor
- 12.30 **The future of medicine regulation in the UK**
Julian Beach, Interim Executive Director, Healthcare Quality and Access, Medicines and Healthcare products Regulatory Agency
Questions and comments from the floor
- 12.55 **Chair's and Westminster Health Forum closing remarks**
Senior Parliamentarian
Jessica Lear, Westminster Health Forum